Danish pharmaceutical company Novo Nordisk has halted deliveries of the diabetes drug Ozempika to Russia, RBC reports, citing a document the manufacturer sent to Roszdravnadzor in advance.
According to the publication, in 2022, the sales volume of this drug in the Russian Federation amounted to more than 2 billion rubles. The drug, among other things, helps in the fight against excess weight. By law, the company must notify the suspension or termination of the supply of any medication in advance.
Roszdravnadzor confirmed that the manufacturer had fulfilled its obligation: a corresponding warning was sent in November last year.
At the same time, the Roszdravnadzor press service draws attention to the fact that at least until December 2023 the drug will still be delivered to Russia.
“Ozempic” is a drug in demand in Russia. In 2021, it was sold in the state segment for 18.66 million rubles. Sales in pharmacies amounted to 1.23 billion rubles. In 2022, the figures increased many times, in the state segment it was sold for almost 600 million rubles, through pharmacies – for 2.2 billion rubles. Such data is provided by the marketing agency DSM Group.
Previously, the American company Viatris stopped supplying the drug Viagra to Russia in order to maintain potency. After that, in two days, the demand for the drug in the country doubled.
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.